Novartis Ag ADR (NVS) Stock Price, Quote & News

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 41 61 324 11 11

Fax: 41 61 324 78 26

Website: www.novartis.com

Address:

Lichtstrasse 35, Basel, Switzerland

Quantumup May. 12 at 7:08 PM

Guggenheim y'day🏁 $ELVN Buy; $80—its PT is supported by conservative assumptions for ELVN-001 (75% PoS in 2L CML, 50% peak shr, 25% PoS in 1L CML, 20% peak shr)= $2.9B risk-adj'd US peak sales in 2043—up to $5B peak. TERN - $MRK $NVS Here's what Guggenheim said in its initiation report: https://x.com/Quantumup1/status/2054276939058176483?s=20

0 · Reply

nnnuuu May. 12 at 5:42 PM

$NVS news soon on lp(a)horizon?

0 · Reply

Quantumup May. 12 at 11:55 AM

Stephens🏁 $PVLA OW; $220, and said, (Q)TORIN' Through Rare Skin Diseases; Initiating OW/Vol. $TARA $NVS PFE Here's what else Stephens said in its initiation report: https://x.com/Quantumup1/status/2054167804635382106?s=20

0 · Reply

Fingerlickengood May. 11 at 12:42 PM

$CDXS $NVS Especially after considering Codexis’ existing partnerships in India for enzymatic drug manufacturing! https://www.globenewswire.com/news-release/2021/10/18/2315614/24825/en/codexis-almelo-and-rc2-announce-a-tri-party-collaboration-for-the-enzymatic-production-of-low-cost-sitagliptin-api-for-the-generic-market-including-a-license-to-codexis-enzyme-tech.html

1 · Reply

Fingerlickengood May. 11 at 12:37 PM

$CDXS $NVS Lots of potential here! “India played a major role in several global therapies, including Coartem Baby, cardiovascular drug Inclisiran (Sybrava), and prostate cancer therapy Pluvicto. Our philosophy has been to transform into a pure-play innovative medicines company,” Dube told TOI, adding that Novartis remains committed to India with over 9,000 employees and plans to launch more new molecules in the coming years.“ https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/novartis-expands-india-role-in-global-drug-development/amp_articleshow/131009829.cms

0 · Reply

Quantumup May. 11 at 10:49 AM

Oppenheimer⬇️ $CRNX's PT to $84 from $87, reiterated at Outperform, and said: CRNX posted $10.7M in total revenue, above our/cons estimates of $7.0M/$8.5M as Palsonify's launch gathers steam. $AZN PFE $NVS IPSEY NBIS SPRB XERS Oppenheimer added—Phase 3 trial in carcinoid syndrome continues its enrollment, and atumelnant is moving along in its respective pivotal and Phase 2 trials in adult and pediatric CAH with a Phase 2/3 to soon begin in ACTH-dependent Cushing syndrome. We have our eye on CRN09682's initial clinical reveal in neuroendocrine tumors, which we believe will come toward year-end. Cash runway into 2030. Current levels may reflect a relative paucity of upcoming catalysts, but we believe today's buyers will be rewarded as CRNX's growing endocrine portfolio marks commercial and clinical success.

0 · Reply

RadioIsotope25 May. 10 at 6:57 PM

$RADX $NVS $CATX $LNTH Huge Radiopharmaceutical Conference

3 · Reply

Fingerlickengood May. 9 at 11:00 AM

$CDXS If this is $NVS, which I am 98% confident it will be, this will be the first HUGE step in their licensing of EcoSythesis for potentially over 20 siRNA drugs tied to Novartis through their associations with both Argo Biopharma and Avidity Biosciences! And that is just the tip of the iceberg! https://www.biospace.com/business/novartis-spending-spree-continues-with-5-2b-argo-sirna-pact https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline

2 · Reply

Fingerlickengood May. 8 at 5:43 PM

$CDXS $NVS without saying it explicitly, thry’ve implied it implicitly! $10++ upon official licensing my assesment! https://www.codexis.com/blogs/accelerating-scalable-and-sustainable-sirna-manufacturing-with-ligation-based-synthesis/

1 · Reply

Quantumup May. 8 at 10:24 AM

Citizens⬇️ $CRNX's PT to $95 (was $97) and reiterated at a Market Outperform rating. $NVS $PFE IPSEY NBIX Here's what Citizens said in its note to investors: https://x.com/Quantumup1/status/2052695584620917236?s=20

0 · Reply

Novartis breaks ground on radioligand therapy manufacturing site in Texas

May 7, 2026, 9:00 AM EDT - 5 days ago

Market Cap	277.12B
Revenue (ttm)	56.67B
Net Income (ttm)	13.98B
EPS (ttm)	N/A
PE Ratio	16.80
Forward PE	16.51
Profit Margin	24.67%
Debt to Equity Ratio	1.16

Volume	921,700
Avg Vol	1,836,240
Day's Range	N/A - N/A
Shares Out	1.91B
Stochastic %K	86%
Beta	0.46
Analysts	Sell
Price Target	$147.95